Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Chunxia Su
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer
Abstract Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EVIDENCE trial, which includes patients with stage II–IIIA resected EGFR-mutated NSCLC who have received either adjuvant icotinib or chemotherapy.
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial
Abstract Although immunotherapy is approved for patients with high PD-L1 expression, optimal therapeutic strategies for PD-L1-negative populations remain undefined. This study (ChiCTR2300071681) assessed the efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy in patients with PD-L1-negative advanced non-small-cell lung cancer (NSCLC).
Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion
ADCs Antibody-Drug Conjugates AEs Adverse Events ALK Anaplastic Lymphoma Kinase ctDNA Circulating Tumour DNA EGFR Epidermal Growth Factor Receptor EGFRm Epidermal Growth Factor Receptor Mutant ESMO European Society For Medical Oncology IHC Immunohistochemistry IV Intravenous MET Mesenchymal Epithelial Transition NGS Next-Generation Sequencing NSCLC Non-Small Cell Lung Cancer NTRK Neurotrophic Tyrosine Receptor Kinase OS Overall Survival PCR Polymerase Chain Reaction PD-L1 Programmed...
Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts
|
1Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China 2Chongqing Key Laboratory of Immunotherapy, Chongqing 400037, China 3College of Basic Medicine, Chongqing Medical University, Chongqing 400016, China 4Research Institute, GloriousMed Clinical Laboratory (Shanghai) Co., Ltd., Shanghai 201318, China 5Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No.507, Zhengmin Road, Shanghai 200433, China...
By Jia-Nan Cheng, Zheng Jin, Chunxia Su, Tao Jiang, Xiaobin Zheng, Jinming Guo, Xingyi Li, Han Chu, Jia Jia, Qin Zhou, Xiaofang Ding, Yiwen Zhang, Shouxia Xu, Fancong Dong, Qiao Zhang, Xinxin Yang, Tao Yang, Xiaoming Cheng, Haoran Zha, Degao Chen, Yisong Wan, Xindong Liu, Lilin Ye, Haidong Tang, Alistair Symonds, Qi-Jing Li, Qingzhu Jia, Bo Zhu
|
Cell Press
Verified
UAV-Assisted Wireless Charging Incentive Mechanism Design Based on Contract Theory
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment
Introduction In recent decades, lung cancer has remained the most lethal type of cancer. According to the 2020 global cancer statistics (1), there were 1.8 million deaths from lung cancer, far surpassing other cancer types and posing a serious threat to people’s health and lives. While lung cancer frequently occurs in individuals over the age of 60, its incidence has been gradually increasing in the younger female population in recent years (2, 3).
Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
Introduction Pulmonary sarcomatoid carcinoma (PSC) accounts for approximately 0.1%–0.5% of lung malignant tumors (1). The histological studies suggest that PSC is a group of transformed carcinoma that originates from the same primitive epithelium and forms after epithelial-mesenchymal transition (EMT).
Segmentectomy for NSCLC: a better alternative?
Nakao et al (2012) 3 Nakao M Yoshida J Goto K et al. Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. Prospective study NA 40 ≤2 cm tumour size, CTR ≤0·50 Sublobar resection (n=26) vs lobectomy (n=14) NA NA 5-year relapse-free survival, 100% in both groups Tsutani et al (2014) 4 Tsutani Y Miyata Y Nakayama H et al.
Highlights • The genomic characteristics and mutations in Notch signaling pathway-related genes of SCLC patients were clarified. • The relationship of Notch signaling pathway mutations with tumor immune microenvironment were analyzed. • There was a significant negative correlation between NOTCH 1 gene mutation status and PD-L1 protein expression level.
The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer
Oct 01, 2021 Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body of evidence suggests fusions in NRG1 (neuregulin 1) will emerge as yet another relevant genomic target. NRG1 fusions are rare events, present across tumor types and seen in about 0.3% of NSCLC cases.1 They tend to be mutually exclusive with other oncogenic driver mutations.
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial - The Lancet Respiratory Medicine
Summary Background Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to compare icotinib with chemotherapy in patients with EGFR-mutant stage II–IIIA NSCLC after complete tumour resection. Here, we report the results from the preplanned interim analysis of the study.
HOTAIR induces EGFR-TKIs Resistance in Non-Small Cell Lung Cancer through Epithelial-Mesenchymal Transition
Highlights • Down-regulation of HOTAIR was associated with EGFR-TKIs resistance. • HOTAIR may enhance activation of apoptosis and EMT. • HOTAIR overexpression restored gefitinib sensitivity in EGFR-TKI resistant cell lines. • HOTAIR expression was associated with primary and acquired resistance to EGFR-TKIs and could regulate cell proliferation through activating cell apoptosis and EMT. • HOTAIR might be able to act as a biomarker to predict the EGFR-TKIs resistance.
Lung Cancer
Lung Cancer
The changing diagnostic pathway for lung cancer patients in Shanghai, China
Publication HistoryPublished online: August 17, 2017Accepted: July 22, 2017; Received in revised form: July 17, 2017; Received: April 9, 2017;
Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge -
Publication HistoryPublished online: July 29, 2017Accepted: July 3, 2017; Received in revised form: June 28, 2017; Received: April 23, 2017;
Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules - Lung Cancer
Publication HistoryPublished online: March 27, 2017Accepted: March 25, 2017; Received in revised form: January 27, 2017; Received: August 7, 2016;
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Chunxia
Contact Chunxia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack